title: Liposarcoma: molecular targets and therapeutic implications.
abstract: Liposarcoma (LPS) is the most common soft tissue sarcoma and accounts for approximately 20 % of all adult sarcomas. Current treatment modalities (surgery, chemotherapy, and radiotherapy) all have limitations; therefore, molecularly driven studies are needed to improve the identification and increased understanding of genetic and epigenetic deregulations in LPS if we are to successfully target specific tumorigenic drivers. It can be anticipated that such biology-driven therapeutics will improve treatments by selectively deleting cancer cells while sparing normal tissues. This review will focus on several therapeutically actionable molecular markers identified in well-differentiated LPS and dedifferentiated LPS, highlighting their potential clinical applicability.
authors.affiliation: The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.|Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, The Ohio State University, 410W 10th Ave., Columbus, OH, 43210, USA.
authors.forename: Kate Lynn J
authors.initials: KL
authors.lastname: Bill
authors.affiliation: The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.|Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, The Ohio State University, 410W 10th Ave., Columbus, OH, 43210, USA.
authors.forename: Lucia
authors.initials: L
authors.lastname: Casadei
authors.affiliation: The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.|Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, The Ohio State University, 410W 10th Ave., Columbus, OH, 43210, USA.
authors.forename: Bethany C
authors.initials: BC
authors.lastname: Prudner
authors.affiliation: The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.|Department of Pathology, The Ohio State University, Columbus, OH, USA.
authors.forename: Hans
authors.initials: H
authors.lastname: Iwenofu
authors.affiliation: The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.|Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, The Ohio State University, 410W 10th Ave., Columbus, OH, 43210, USA.|Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH, USA.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Strohecker
authors.affiliation: The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Raphael.Pollock@osumc.edu.|Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, The Ohio State University, 410W 10th Ave., Columbus, OH, 43210, USA. Raphael.Pollock@osumc.edu.
authors.forename: Raphael E
authors.initials: RE
authors.lastname: Pollock
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D008080:Liposarcoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D058990:Molecular Targeted Therapy
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs
keywords: 12q13–15 amplicons; Biomarker; Dedifferentiated liposarcoma; Exosome; MDM2; Molecular-cytogenetic analysis; miRNAs